Skip to main content

Table 3 Details of irAEs observed in this study

From: CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab

 

Grade 1

Grade 2

Grade 3

Grade 4

Grade 5

Any grade

Hypothyroidism

1

4

0

0

0

5

Liver

0

0

0

1

0

1

Diarrhea / colitis

2

1

2

0

0

5

Adrenal insufficiency

0

1

0

0

0

1

Rash

0

2

0

0

0

2

Peripheral motor neuropathy

0

1

0

0

0

1

Total

3

9

2

1

0

15

  1. irAEs, Immune-related adverse events